Ziel
Chronic hepatitis C is one of the most common chronic viral infections of humans and a major cause of chronic liver disease, cirrhosis and liver cancer. Still about 4 million new infections occur world-wide each year with 50-85% of patients progressing to chronic hepatitis C. Currently there is no marker to predict spontaneous viral clearance and to guide treatment decisions.
The major objectives of the HepaCute proposal are to develop biomarkers predicting the outcome of acute hepatitis C, improving the management of the related patients and thus decreasing the health burden of hepatitis C in Europe and Mediterranean partner countries (MPC).
The HepaCute consortium has evolved from a series of EC-funded projects on hepatitis C (HCVacc/HepCvax/Virgil/HEPACIVAC) and consists of world leading experts in HCV epidemiology, immunology, and virology, including partners from Egypt and Morocco, who have strongly influenced the current management of patients with acute hepatitis C in their respective regions, and contributed considerably to our understanding of mechanisms of spontaneous viral clearance. The HepaCute proposal is closely connected to ongoing national, European, and Egyptian networks on HCV research (HepNet, EASL, STDF), which will support HepaCute to make it a success.Together with another pertinent EU-funded research project, SPHINX, it actively contributes to coordinating EU-funded hepatitis C research with pertinent research projects funded in the MCP countries, in particular with hepatitis research projects funded under the Egyptian Science and Technology Development Fund (STDF).
Within HepaCute the most innovative technologies will be employed such as genome-wide association studies, transcriptomics, proteomics, and ultra-deep sequencing to better understand the early events in acute hepatitis C and to translate these results into readily practicable diagnostic tools to predict spontaneous viral clearance.
HepaCute has firmly integrated partners from Egypt and Morocco with preexisting research collaborations with European partners into the scientific research programm and we expect this continuing partnership between European and Mediterranean countries to have a strong impact on the care of patients with acute hepatitis C both in Europe and MPC.
Wissenschaftliches Gebiet
- medical and health sciencesclinical medicineoncologyliver cancer
- medical and health scienceshealth sciencespublic healthepidemiology
- medical and health scienceshealth sciencesinfectious diseasesRNA viruseshepatitis C
- medical and health sciencesbasic medicineimmunology
- medical and health sciencesclinical medicinehepatology
Programm/Programme
Aufforderung zur Vorschlagseinreichung
FP7-HEALTH-2010-single-stage
Andere Projekte für diesen Aufruf anzeigen
Finanzierungsplan
CP-FP-SICA - Small/medium-scale focused research project for specific cooperation actions dedicated to international cooperation partner countries(SICA)Koordinator
81377 Munchen
Deutschland
Auf der Karte ansehen
Beteiligte (16)
75015 PARIS
Auf der Karte ansehen
30625 Hannover
Auf der Karte ansehen
79106 Freiburg
Auf der Karte ansehen
43100 Parma
Auf der Karte ansehen
31008 Pamplona
Auf der Karte ansehen
1211 Geneve
Auf der Karte ansehen
B15 2TT Birmingham
Auf der Karte ansehen
SW7 2AZ LONDON
Auf der Karte ansehen
75654 Paris
Auf der Karte ansehen
30659 Hannover
Auf der Karte ansehen
22311 GIZA
Auf der Karte ansehen
32511 MENOUFIYA
Auf der Karte ansehen
12311 Cairo
Auf der Karte ansehen
1011 Lausanne
Auf der Karte ansehen
50937 Koeln
Auf der Karte ansehen
20360 Casablanca
Auf der Karte ansehen